[ad_1]
SEATTLE, WA, July 05, 2018 (GLOBE NEWSWIRE) – CFN Media Group ("CFN Media"), the leading network of agencies and financial media dedicated to the North American cannabis industry, announced today the publication of an article on Lexaria Biosciences Inc. (CSE: LXX) (LXX.CN) (CNSX: LXX) (OTCQX: LXRP), which at l Originally developed its platform DehydraTECH ™ to increase the bioavailability of cannabinoids. The company has since expanded its field of action far beyond the cannabis industry. A recent discovery suggests that the proprietary platform can be effective in enabling researchers to deliver APIs beyond the blood-brain barrier. And investors may want to take note of these developments.
The blood-brain barrier is very effective in protecting the brain against blood-borne pathogens, but it makes it difficult to treat many disorders of the nervous system. Although there are several techniques that researchers have tried, they only work with a small subset of active pharmaceutical ingredients. There is no widely used solution that allows researchers to incorporate any active ingredient and effectively reach the brain.
Challenges of the Blood-Brain Barrier
The blood-brain barrier is designed to protect the brain against circulating toxins. blood flow. Most charged molecules and molecules of more than 700 Daltons are unable to pbad through the barrier, and smaller molecules are often conjugated in the liver. A leaking blood-brain barrier is badociated with neurological diseases, such as epilepsy, traumatic brain injury and edema, and with systemic diseases, such as liver failure.
The blood-brain barrier helps protect the brain. and disorders of the brain and central nervous system, such as Alzheimer's disease, Parkinson's disease, bacterial and viral infections and brain cancers. Many traditional pharmaceuticals are trying to get around these problems by creating liposome-based transporters, synthesizing polymers or linking the drug to a carrier – but each method has its drawbacks.
Researchers continue to research new innovative ingredient technologies, or APIs, to cross the blood-brain barrier without degrading or becoming less effective. For example, insulin can be transported across the blood-brain barrier, but the carrier's specificity is too high for most pharmacological agents covalently bound to insulin to cross the barrier.
Benefits DehydraTECH ™
Lexaria Biosciences recently announced that its DehydraTECH ™ drug delivery platform demonstrated improved drug delivery to brain tissue. In particular, in vivo studies on nicotine showed that up to 560 percent more nicotine was administered to DehydraTECH ™ compared to DehydraTECH ™ depleted controls – which combine or join with APIs for supplementation. maximum.
Researchers first focused on the development of nicotine replacement products. After all, the company could develop oral nicotine products with the same effect as inhaled nicotine, but without the harmful carcinogenic effects of burning. But, the surprising discovery also suggests that DehydraTECH ™ could have a much more important role in the treatment of nervous system disorders by effectively transporting across the blood-brain barrier
. After the discovery, the company filed a new application for patent with the USPTO treatment options for diseases and disorders of the central nervous system, including ADHD, anxiety, depression, obsessive-compulsive disorder, schizophrenia, dementia. Alzheimer's, Huntington's, Parkinson's, neuropathic pain, and more. The company hopes to take advantage of this patent in the future to develop or award innovative new products using its DehydraTECH ™ platform.
Looking Ahead
Lexaria Biosciences Inc. (OTCQX: LXRP) represents an exciting opportunity in the biotech space with its DehydraTECH ™ platform. With approximately 50 patents issued or pending worldwide, the company has made tremendous progress in building its DehydraTECH ™ franchise to include the delivery of cannabinoids, terpenes, terpenoids, NSAIDs, vitamins, nicotine, testosterone and many other drugs. information, visit the company's website at: https://www.lexariabioscience.com .
Please click on the link to read the full article: http://www.cannabisfn.com/lexaria-dehydratech-shows-promise-nervous-system-disorders/
About CFN Media
CFN Media (CannabisFN) is the leading network of agencies and financial media dedicated to the global cannabis industry. It helps companies operating in the area to attract investors, capital and advertising. Since 2013, private and public cannabis companies in the United States and Canada rely on CFN Media to grow and succeed.
Learn how to become a CFN Media company, brand or contractor: http: //www.cannabisfn .com / featuredcompany
Download the CFN Media iOS Mobile App for to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247? ls = 1 & mt = 8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http : //www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial advisor or broker. You should always consult your own legal, tax and / or independent investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the "Site") is original financial news or paid advertising written by our internal team or provided by an affiliate. CannabisFN.com, a financial media and marketing agency, enters into media contracts or service contracts with companies that are the subject of articles published on the Site or other editorials for the advertising of these companies. We are not an independent provider of news media. We make no warranties or representations about the information, including its completeness, accuracy, truthfulness or reliability and we expressly and implicitly disclaim all warranties of any kind, including if the information is complete, exact, truthful or reliable. As such, your use of information is at your own risk. We take no obligation to update posted articles. CannabisFN.com has received compensation for the production and presentation of sophisticated and high quality content on CannabisFN.com as well as financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, owner of CannabisFN.com and CFN Media, has been hired to raise awareness. Please follow the link below to see our full statement describing our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane 206-369-7050 [email protected]
Source link
